The company was founded 2021 based on a discovery by Dr Lei Chen, PhD in molecular biology and a member of Professor Ulf Landegrens team at the Department of Immunology, Genomics and Pathology at Uppsala University.
Rarity Biosciences was founded in 2021 as a spin out from Uppsala University to further develop and commercialize the superRCA assay technology.
The superRCA technology was first discovered and developed in 2015 by PhD Lei Chen and Professor Ulf Landegren in the Molecular Tools group at the Department of Immunology, Genetics, and Pathology. The initial aim was to continue the successful development of padlock probe and rolling circle amplification to generate secondary rolling structures that could increase the signal intensity of existing protocols. As with most scientific discoveries, the path is not always straight, but the superRCA came out as an extremely powerful amplification tool with unique allele distinction suitable for single variant mutation detection.
The first application in Leukemia was studied together with Uppsala Academic Hospital and SciLifeLab during 2018-2020 as a retrospective benchmarking study that showed that the Rarity superRCA was able to detect common mutations in Acute myeloid leukemia (AML) with a greater sensitivity than current test practice i.e. ddPCR and NGS. In addition, a study of multiple follow-up samples showed that relapse could have been detected up to three months earlier. (Lei et al. Nature Communication)
Our vision is to democratize mutation detection.
Our mission is to improve clinical decisions and patient outcome by offering fast, sensitive, and reliable mutation detection technology at the right time.
Linus Bosaeus
CEO
Director of Operations (2019-2021) and VP Operations Clinical Trials (2021) at NuvoAir. Head of Development (2012-2016) and CEO (2016-2018) at Endovab. Research Engineer and FOI including risk management and long term planning. Board member at Endovab, and Muntra, a cloud based journal system for dental care.
Lei Chen
CO-FOUNDER & CTO
Bachelor’s Degree in biotechnology (2004-2008) at Nanjing University, China. Master’s Degree in Applied Biotechnology (2008-2010) at Uppsala University, Sweden. Host seminars in Liquid Biopsy course at EMBL (2018-2021). Active collaborations with the IVD industry on the consulting base.
Hanna Kocken
HEAD OF QUALITY AND REGULATORY
Thermo Fisher Scientific (2022-2015): Senior Manager Research & Development, Acting Director Regulatory Affairs, Quality and Regulatory Lead. ÅF/AFRY (2015-2011): Product Compliance Consultant, assignments for IVD, Medical Device and Life Science business. Bactiguard (2011-2005): Quality System Manager, Technical Product Manager, Project Manager. MeTaCot (2005-2003): Research Engineer.
Mikael Smedeby
CO-FOUNDER, CHAIRMAN OF THE BOARD
General Counsel, Structures Freemont SA. Active as a lawyer since 1994. Member of the Swedish Bar Association. Executive positions at Advokatfirman Lindahl, including Managing Partner and Chairman of the Board. Member of the Board of Directors of BioArctic, 2014–2017. Special experience in corporate law, mergers and acquisitions, financing and licensing.
Ulf Landegren
CO-FOUNDER & BOARD MEMBER
Nils Landegren
BOARD MEMBER
Per Matsson
CO-FOUNDER, DEPT CHAIRMAN OF THE BOARD
Head of R&D (immunology) at Sanofi Diagnostics Pasteur Inc. VP of R&D at Pharmacia Diagnostics AB, with development and registration of diagnostic products throughout the world including Europe, US and Japan.
Idar Kreutzer
BOARD MEMBER
Former member of the World Business Council for Sustainable Development (WBCSD) and has Co-Chaired their Vision 2050. Former member of The Norwegian Commission for Green Competitiveness (2015-2016). Appointed member of the Strategy Council for the Norwegian Government Pension Fund Global in 2013.
Ove Öhman
ADVISOR
Former senior research fellow at J&J and Pharmacia. Serial Entrepreneur, with several successful ventures.
At Rarity Bioscience we are aiming at radically improving cancer diagnostic. We are developing a technology with the power of saving people’s lives.
Our journey has just started, and we look forward to expand the team.
Please read the application and apply within
Are you our new Director of Business Developer? If you are ready to join the future of precision diagnostics, we are now hiring another a key role for our mission to make mutation detection technology available to all patients, clinicians and researchers.
Please submit your application now.
Sitemap
Contact us
